Lung Cancer Trials Ask AI to find trials
CompletedPhase 1NCT01451632
Official study title

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Study summary

The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMM-121 and Irinotecan

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · EGFR

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 8, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?Merrimack Pharmaceuticals

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Merrimack Pharmaceuticals
Interventions being studied
Drug: MM-121; Drug: Irinotecan; Drug: Cetuximab
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Biomarkers
EGFR→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • No standard options remaining
  • Adequate liver and kidney functions
  • 18 years of age or above
Reasons someone may not be able to joinExclusion criteria
  • History of any secondary active cancer in the last 3 years.
  • Pregnant or breast feeding
  • History of severe allergic reactions or contraindications to cetuximab or irinotecan

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Study locationSan Francisco, California
  • Study locationBoston, Massachusetts
  • Study locationChapel Hill, North Carolina
  • Study locationSalt Lake City, Utah

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 8, 2016. Always confirm current availability with the study team.

View original record ↗